Quantum-Informed Holistic Hormonal Therapy (QHHT): A Unified Multidisciplinary Framework for Treating Female-Specific Cancers through Non-Equilibrium Hormonal and Cellular Reprogramming

Quantum-Informed Holistic Hormonal Therapy (QHHT) introduces a comprehensive framework for managing female-specific cancers, including breast, ovarian, endometrial, and cervical cancers, by precisely modulating the Dynamic Hormonal Field (DHF) through the integration of quantum chemistry, non-equilibrium thermodynamics, and multiscale computational modeling. This methodology employs time-dependent density functional theory (TD-DFT), quantum mechanics/molecular mechanics (QM/MM) hybrid simulations, and advanced molecular docking techniques for ligand optimization; non-equilibrium thermodynamics framed by fluctuation-dissipation theorems and Bayesian statistical inference; and hierarchical modeling utilizing physics-informed neural networks (PINNs), graph neural networks (GNNs), and constrained safe reinforcement learning (RL). Oncogenic phenotypes are characterized as departures from the minimum entropy production principle (MinEP), quantified via excess entropy production σ_cancer = σ_system - σ_MinEP, which emerges as a robust, scale-invariant biomarker. Entropy production components (σ_chemical, σ_transport) are rigorously estimated using non-equilibrium molecular dynamics (NEMD), isothermal titration calorimetry (ITC), and Förster resonance energy transfer (FRET) spectroscopy, with statistical rigor ensured through Markov chain Monte Carlo (MCMC) sampling, maximum likelihood estimation (MLE), and convergence diagnostics (e.g., Gelman-Rubin \hat{R} < 1.01). Therapeutic optimization leverages safe RL to mitigate off-target toxicities, augmented by SHapley Additive exPlanations (SHAP) for model interpretability. Empirical correlations with TCGA clinical datasets (e.g., Ki-67 proliferation index, Spearman's ρ = 0.68, p < 0.001) are substantiated, albeit with the caveat of requiring prospective in vivo validation. Sensitivity analyses via Sobol' indices and Morris methods confirm model robustness (± 8% variation in key parameters). QHHT advances precision oncology by targeting entropic dysregulation at multiple scales, while critically addressing assumptions in current computational paradigms and advocating for rigorous experimental corroboration.